- Home
- NAAS vs BCDA Comparison
NAAS vs BCDA Comparison
Compare NAAS & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAAS
- BCDA
- Stock Information
- Founded
- NAAS 2019
- BCDA N/A
- Country
- NAAS China
- BCDA United States
- Employees
- NAAS N/A
- BCDA N/A
- Industry
- NAAS Other Specialty Stores
- BCDA Biotechnology: Pharmaceutical Preparations
- Sector
- NAAS Consumer Discretionary
- BCDA Health Care
- Exchange
- NAAS Nasdaq
- BCDA Nasdaq
- Market Cap
- NAAS 8.3M
- BCDA 9.4M
- IPO Year
- NAAS 2017
- BCDA N/A
- Fundamental
- Price
- NAAS $1.23
- BCDA $2.85
- Analyst Decision
- NAAS
- BCDA Strong Buy
- Analyst Count
- NAAS 0
- BCDA 1
- Target Price
- NAAS N/A
- BCDA $25.00
- AVG Volume (30 Days)
- NAAS 1.3M
- BCDA 91.2K
- Earning Date
- NAAS 05-20-2025
- BCDA 05-20-2025
- Dividend Yield
- NAAS N/A
- BCDA N/A
- EPS Growth
- NAAS N/A
- BCDA N/A
- EPS
- NAAS N/A
- BCDA N/A
- Revenue
- NAAS $43,258,393.00
- BCDA $58,000.00
- Revenue This Year
- NAAS $19.53
- BCDA N/A
- Revenue Next Year
- NAAS $151.36
- BCDA N/A
- P/E Ratio
- NAAS N/A
- BCDA N/A
- Revenue Growth
- NAAS 50.34
- BCDA N/A
- 52 Week Low
- NAAS $1.23
- BCDA $1.63
- 52 Week High
- NAAS $76.80
- BCDA $6.15
- Technical
- Relative Strength Index (RSI)
- NAAS 27.23
- BCDA 60.80
- Support Level
- NAAS $1.18
- BCDA $2.40
- Resistance Level
- NAAS $3.49
- BCDA $3.17
- Average True Range (ATR)
- NAAS 0.28
- BCDA 0.28
- MACD
- NAAS 0.04
- BCDA 0.07
- Stochastic Oscillator
- NAAS 2.16
- BCDA 76.19
About NAAS NaaS Technology Inc.
Naas Technology Inc is an electric vehicle charging service provider in China, whose vision is to power the world with carbon-neutral energy. It offers an integrated set of online solutions to charging station operators. wide range of offline services that simplify the daily operations of charging station operators, and of non-charging services such as food and beverage services to station operators.
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).